AXSM Maintained by Deutsche Bank -- Price Target Lowered to $267

gurufocus.com · 2026-09-29

Axsome Therapeutics (AXSM) Analyst Rating Update On September 29, 2026, Deutsche Bank analyst David Hoang maintained a Buy rating on Axsome Therapeutics (AXS

Read the full story at gurufocus.com →